Learn from failures and stay hopeful to GPR40, a GPCR target with robust efficacy, for therapy of metabolic disorders by Hong-Ping Guan, Yusheng Xiong

“…For its involvement in satiety regulation and metabolic homeostasis, partial and AgoPAM (Positive Allosteric Modulation agonist) GPR40 agonists had been developed for type 2 diabetes (T2D) by many pharmaceutical companies. The proof-of-concept of GPR40 for control of hyperglycemia was achieved by clinical trials of partial GPR40 agonist, TAK-875, demonstrating a robust decrease in HbA1c (-1.12%) after chronic treatment in T2D. …”
Get full text

Scoping Review of International Experience of a Dedicated Fund to Support Patient Access to Cancer Drugs: Policy Implications for Thailand by Parnnaphat Luksameesate, Osot Nerapusee, Chanthawat Patikorn, Puree Anantachoti

“…In England and Italy, pharmaceutical companies contribute proportionally to cover overspending as per risk-sharing agreements, while cost-sharing is not required. …”
Get full text

The impact of perceived organizational support and resilience on pharmacists’ engagement in their stressful and competitive workplaces in Saudi Arabia by Hussain Abdulrahman Al-Omar, Azher Mustafa Arafah, Jehan Mohammed Barakat, Reem Dhayan Almutairi, Fowad Khurshid, Mohammed Sultan Alsultan

“…Those pharmacists were assigned in highly competitive jobs within organizations such as pharmaceutical companies, hospitals and pharmaceutical distributors. …”
Get full text

Analysis of the list of dugs for the treatment of bronchial asthma in children acording to state form by K. L. Kosyachenko, I. A. Kostiuk

“…The analysis allows producing countries to establish that 87% of the analyzed group of drugs manufactured by foreign pharmaceutical companies, and only 13% – domestic. This production represented 20 foreign countries and domestic – 10 companies. …”
Get full text

Medicine procurement in hospital pharmacies of Nepal: A qualitative study based on the Basel Statements. by Mina Shrestha, Rebekah Moles, Eurek Ranjit, Betty Chaar

“…Most had no formulary and procured medicines solely based on doctors' prescriptions, which were heavily influenced by pharmaceutical companies' marketing strategies. Whilst most procured only registered medicines, a minority reported purchasing unregistered medicines through unauthorised supply-chains. …”
Get full text

Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world by Vivek P. Chavda, Qian Yao, Lalitkumar K. Vora, Vasso Apostolopoulos, Chirag A. Patel, Rajashri Bezbaruah, Aayushi B. Patel, Zhe-Sheng Chen

“…With an immediate worldwide effort, communication, and sharing of data, large amounts of funding, researchers and pharmaceutical companies immediately fast-tracked vaccine development in order to prevent severe disease, hospitalizations and death. …”
Get full text

A Revisit to the Research Updates of Drugs, Vaccines, and Bioinformatics Approaches in Combating COVID-19 Pandemic by Tofael Ahmed Sumon, Md. Ashraf Hussain, Md. Tawheed Hasan, Mahmudul Hasan, Won Je Jang, Eleus Hussain Bhuiya, Abdullah Al Mamun Chowdhury, S. M. Sharifuzzaman, Christopher Lyon Brown, Hyun-Ju Kwon, Eun-Woo Lee

“…Although SARS-CoV-2 is genetically similar to other coronaviruses, i.e., SARS and Middle East respiratory syndrome coronavirus (MERS-CoV), no confirmed therapeutics are yet available against COVID-19, and governments, scientists, and pharmaceutical companies worldwide are working together in search for effective drugs and vaccines. …”
Get full text

An Evaluating the efficacy of a traditional approach to marketing in the South African pharmaceutical industry during the Covid19 pandemic by Thembisa Khuboni

“…It highlights the need for pharmaceutical companies to adapt their strategies and incorporate digital platforms into their marketing efforts. …”
Get full text

Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase (RTK) inhibitors for RTK-rearranged (ROS1... by Sai-Hong Ignatius Ou

“…Pfizer, the manufacturer of crizotinib, sponsored the screening of thousands of patients and the standardization of the ALK FISH test as part of the approval process for crizotinib, a first in class ALK inhibitor. Many pharmaceutical companies are now using the FDA-approved ALK FISH assay to enroll patients onto trials for their own respective ALK inhibitors. …”
Get full text

Synthesis, Structure Elucidation, Antibacterial Activities, and Synergistic Effects of Novel Juglone and Naphthazarin Derivatives Against Clinical Methicillin-Resistant Staphylococ... by Valentin Duvauchelle, Chaimae Majdi, David Bénimélis, Catherine Dunyach-Remy, Patrick Meffre, Zohra Benfodda

“…Moreover, in recent years, very few antibiotics have been discovered and developed by pharmaceutical companies. Therefore, there is an urgent need to discover and develop new antibacterial agents to combat multidrug-resistant bacteria. …”
Get full text

What the public was saying about the H1N1 vaccine: perceptions and issues discussed in on-line comments during the 2009 H1N1 pandemic. by Natalie Henrich, Bev Holmes

“…The following seven themes were mentioned in at least 5% of the comments (% indicates the percentage of comments that included the theme): fear of H1N1 (18.8%); responsibility of media (17.8%); government competency (17.7%); government trustworthiness (10.7%); fear of H1N1 vaccine (8.1%); pharmaceutical companies (7.6%); and personal protective measures (5.8%). …”
Get full text

Physicians’ attitudes, knowledge, and practices regarding antibiotic prescriptions by Fatma Al Rahbi, Issa Al Salmi, Faryal Khamis, Zakaria Al Balushi, Nenad Pandak, Eskild Petersen, Suad Hannawi

“…Other factors contributing to AMR such as lack of local hospital guidelines on antibiotic usage, random mutations in microbes, patient demands and expectations for antibiotics, and the role of pharmaceutical companies in advertising and promoting use of antibiotics were deemed important by 33.3%, 26.8%, 22.5% and 20.4%, respectively. …”
Get full text

Discrimination of Gastrodia elata from Different Geographical Origin for Quality Evaluation Using Newly-Build Near Infrared Spectrum Coupled with Multivariate Analysis by Yamin Zuo, Xuehua Deng, Qing Wu

“…Discrimination of Gastrodia elata (G. elata) geographical origin is of great importance to pharmaceutical companies and consumers in China. this paper focuses on the feasibility of near infrared spectrum (NIRS) combined multivariate analysis as a rapid and non-destructive method to prove its fit for this purpose. …”
Get full text

Romo1-Derived Antimicrobial Peptide Is a New Antimicrobial Agent against Multidrug-Resistant Bacteria in a Murine Model of Sepsis by Hye-Ra Lee, Deok-gyun You, Hong Kyu Kim, Jang Wook Sohn, Min Ja Kim, Jong Kuk Park, Gi Young Lee, Young Do Yoo

“…Unfortunately, these antibiotics have mainly been developed to cure bacterial skin infections rather than others, such as life-threatening sepsis. Major pharmaceutical companies have tried to develop antiseptic drugs; however, they have not been successful. …”
Get full text

Expectations and limitations of E-learning in General Practice (ELGP) by Vollmar, Horst Christian, Waldmann, Uta-Maria, Sönnichsen, Andreas, Gensichen, Jochen

“…The agreement was low (28%) with the thesis “e-learning can be financed by pharmaceutical companies” and very high with the theses “e-learning can be an important stimulus in continuous medical education”, “e-learning gets a new focus by blended-learning concepts”, “e-learning needs a strong orientation towards its users”, and “users will have a higher level of media-competence five years from now” (94% each). …”
Get full text

There's an app for that, but nobody's using it: Insights on improving patient access and adherence to digital therapeutics in Germany by Florian Dahlhausen, Maximillian Zinner, Linn Bieske, Jan P Ehlers, Philip Boehme, Leonard Fehring

“…Results Healthcare professionals were found to have the greatest potential to promote both access and patient adherence to digital therapeutics, followed by health insurers, pharmaceutical companies, and patients themselves. In terms of patient access, healthcare professionals have potential due to their ability to prescribe digital therapeutics. …”
Get full text

Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints. by Aaron S Kesselheim, Michelle M Mello, David M Studdert

“…We developed a typology for the strategies and practices that constitute off-label marketing.We obtained unsealed whistleblower complaints against pharmaceutical companies filed in US federal fraud cases that contained allegations of off-label marketing (January 1996-October 2010) and conducted structured reviews of them. …”
Get full text

Timing and Motivations for Alternative Cancer Therapy With Insights From a Crowdfunding Platform: Cross-sectional Mixed Methods Study by John Peterson, Trevor Wilson, Joshua Gruhl, Sydney Davis, Jaxon Olsen, Matthew Parsons, Benjamin Kann, Angela Fagerlin, Melissa Watt, Skyler Johnson

“…Moreover, on comparing those who started with alternative therapy and those who switched from conventional to alternative therapy, those who started with alternative therapy more often expressed natural and holistic values (49.3% vs 27.0%; P<.001), expressed an unorthodox understanding of cancer (25.5% vs 16.4%; P=.004), referenced religious or spiritual beliefs (15.1% vs 8.9%; P=.01), perceived alternative treatment as efficacious (19.1% vs 10.2%; P=.001), and distrusted pharmaceutical companies (3.2% vs 0.5%; P=.04). …”
Get full text

Potential dual inhibitors of PCSK-9 and HMG-R from natural sources in cardiovascular risk management by Mohd Waiz, Sahir Sultan Alvi, M. Salman Khan

“…Atherosclerotic cardiovascular disease (ASCVD) stands amongst the leading causes of mortality worldwide and has attracted the attention of world’s leading pharmaceutical companies in order to tackle such mortalities. …”
Get full text

Knowledge and Pattern of Antibiotic and Non Narcotic Analgesic Prescription for Pulpal and Periapical Pathologies- A Survey among Dentists by M Jayadev, P Karunakar, B Vishwanath, S Soumya Chinmayi, P Siddhartha, B Chaitanya

“…Factors influencing the choice of analgesics among respondents is severity of pain (61.4%). 31.7% remained informed of current prophylactic practices through pharmaceutical companies followed by university training sessions and scientific societies (30.7%). …”
Get full text